| [1] |
LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang.
Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
|
| [2] |
LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke.
A bioequivalence study of generic and brand clozapine in schizophrenic patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
|
| [3] |
WANG Fei, HANG Yongfu, WANG Wei.
Influence of argumented renal clearance on teicoplannin serum concentrations in critical ill patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1043-1048.
|
| [4] |
HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang.
Comparison of calculation results of five population pharmacokinetic analysis tools
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
|
| [5] |
LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua.
Research progress in population pharmacokinetics of rituximab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
|
| [6] |
YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei.
Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
|
| [7] |
YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong.
Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990.
|
| [8] |
DU Wenpeng, AO Jiangen, TAO Yi, WU Guansheng, HE Jiake.
Study on the factors affecting the steady-state blood concentration of tacrolimus in patients with autoimmune diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 645-651.
|
| [9] |
LIAN Jinfang, LIU Yiwei, LIN Cuihong, HUANG Pinfang, LIN Rongfang.
Comparison of prediction accuracy between warfarin PPK/PD model and multiple regression dose models
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 267-273.
|
| [10] |
WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei.
Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
|
| [11] |
HU Yin, YANG Dandan, XU Yichao, SHAO Rong, RUAN Zourong, JIANG Bo, CHEN Jinliang, LOU Honggang.
Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 63-69.
|
| [12] |
LIU Chang, DENG Kunhong, HUANG Jie, YANG Shuang, YANG Xiaoyan, XIANG Yuxia, HUANG Lu, ZHANG Zeyu, LIANG Wenzhong, LAN Jing, YANG Guoping.
Bioequivalence of moxifloxacin hydrochloride tablets in healthy Chinese subjects
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1393-1399.
|
| [13] |
HAN Guijuan, JIANG Ji, OUYANG Weiwei, LUO Hong, ZHANG Xiaojun, WANG Minghua.
Absorption and excretion of CT-707 in healthy male subjects studied by radioisotope tracer method
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1407-1412.
|
| [14] |
LI Na, HAN Hongcan, WANG Jun.
General considerations for bioequivalence studies with pharmacokinetic methods for anti-schizophrenic drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1419-1425.
|
| [15] |
ZHANG Miao, LIU Qian, YAO Xueting, LIU Dongyang.
Exploration of early food effect study of innovative drugs based on physiologically-based pharmacokinetic absorption model
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1426-1429.
|
